$12.25
-0.25 (-2.00%)
Open$12.51
Previous Close$12.50
Day High$12.59
Day Low$12.09
52W High$69.97
52W Low$9.40
Volume—
Avg Volume507.9K
Market Cap214.39M
P/E Ratio—
EPS$-14.34
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+232.6% upside
Current
$12.25
$12.25
Target
$40.74
$40.74
$28.14
$40.74 avg
$50.62
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 26.95M | 84.57M | 86.26M |
| Net Income | -255,012,975 | -20,699,385 | -25,319,011 |
| Profit Margin | -946.2% | -24.5% | -29.4% |
| EBITDA | -258,814,202 | -24,990,141 | -25,196,528 |
| Free Cash Flow | — | -20,292,095 | -20,848,476 |
| Rev Growth | — | +3.2% | +20.0% |
| Debt/Equity | — | 0.58 | 0.68 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |